The Experts below are selected from a list of 60 Experts worldwide ranked by ideXlab platform

Zhu Tie-bing - One of the best experts on this subject based on the ideXlab platform.

  • Clinical Study of Almagate Suspension on Bile-reflux Gastritis
    Journal of Elinical Research, 2005
    Co-Authors: Zhu Tie-bing
    Abstract:

    【Objective】To observe the clinical effect of Almagate suspension on bile-reflux gastritis and the influence on 24-hour intragastric bile.【Methods】Forty-six patients with bile-reflux gastritis proven by endoscopic examination and 24-hour intragastric bile monitoring were divided into 2 groups at random.Treatment group(n=24) took Almagate suspension and mosapride citrate tablets,the control group(n=22) took mosapride only.The severity of all the symptoms including abdominal pain,abdominal distention,nausea and bile vomitus were investigated four weeks after treatment.Endoscopic examination and 24-hour intragastric bile monitoring were reexamined after treatment.【Results】All the symptoms in the two groups improved greatly.The efficient rates were 95.83% in treatment group and 81.82% in contral group,There were no significant differences between them(P0.05).But the cure rates were 54.17% and 27.27% respectively,there were significant differences between them(P0.05).The total time percentage of 24-hour intragastric bile-reflux had both greatly decreased after treatment(P0.01).The two groups variety rates had significant differences(P0.05).【Conclusion】Almagate Suspension can bind with intragastric bile efficiently.When it and mosapride citrate tablets are used to treat bile-reflux gastritis,there will be significant effect.

Juan V Esplugues - One of the best experts on this subject based on the ideXlab platform.

  • protection by Almagate of ethanol induced gastric mucosal damage in rats
    Journal of Pharmacy and Pharmacology, 2011
    Co-Authors: M D Barrachina, M A Martinezcuesta, Sara Calatayud, L Moreno, A Fernandez, J Puig, Juan V Esplugues
    Abstract:

    The study was designed to analyse the protective effects of Almagate on a model of gastric injury, ethanol-induced mucosal damage, in which acid plays little, if any, role. Pretreatment with Almagate dose-dependently reduced the level of gastric damage induced by oral administration of 1mL 100% ethanol. Administration of 12 μmol kg−1 Almagate 30 min before ethanol significantly reduced the area of mucosal damage by 65 ± 10%, and the maximum level of inhibition (74 ± 11%) was obtained with 150 μmol kg−1 Almagate. Administration of higher doses of Almagate (200–250 μmol kg−1) did not result in any further increase in the level of protection against ethanol-induced gastric damage. Administration of 1 mL 100% ethanol induces substantial damage to the gastric mucosa, with nearly 40% of the length of the section evaluated exhibiting deep necrotic and haemorrhagic damage. Pretreatment with Almagate caused a significant diminution in all parameters of histological damage, whereas damage to the epithelial cell layer was only significantly reduced by pretreatment with the highest doses evaluated (25, 50 and 150 μmol kg−1). Administration of aluminium hydroxide did not modify ethanol-induced mucosal damage, even at doses containing concentrations of aluminium higher than those present in gastroprotective doses of Almagate. Pretreatment with sucralfate, another aluminium containing compound, at doses of 250 μmiol kg−1 protected the mucosa, although lower doses did not. The present study has shown that Almagate prevents ethanol-induced gastric mucosal damage. This protective effect seems independent of any antacid activity, related to its content in magnesium, and mediated by an increase in gastroprotective prostaglandins in the mucosa of the stomach.

Carles Pons - One of the best experts on this subject based on the ideXlab platform.

  • lack of Almagate interference in breath test results for helicobacter pylori diagnosis almatest study
    Gastroenterología y Hepatología, 2020
    Co-Authors: Carles Pons, Modesto Varas, Javier P Gisbert, Merce Barenys, Francesca Pajuelo, Francisco Javier Fernandez
    Abstract:

    Resumen Objetivo El test del aliento con 13C-urea (TAU) es la prueba no invasiva mas utilizada para diagnosticar Helicobacter pylori (H. pylori). La posible interferencia de la toma de antiacidos en su resultado es aun controvertida. El estudio se dirige a confirmar la no interferencia del almagato en la determinacion de H. pylori mediante el TAU. Pacientes y metodos Estudio observacional, multicentrico, en pacientes adultos en tratamiento con almagato y a los que se indico un TAU (TAUKIT®). Cuando el resultado del TAU fue negativo, se suprimio la toma de almagato durante 30 dias y se repitio un segundo TAU. En los pacientes cuyo resultado fue positivo, no se realizaron mas determinaciones. La variable principal a estudio fue el porcentaje de pacientes que teniendo resultado negativo en la primera prueba de aliento, tras suprimir la toma de almagato y repetirla, esta se positivizo (falsos negativos del TAU, posiblemente atribuibles a almagato). Resultados De los 167 pacientes evaluables, 59% fueron mujeres, la media de edad fue de 49 anos y 97% de los casos presentaban sintomatologia digestiva. El resultado del primer TAU fue negativo en un 71% de casos. De estos, en la segunda prueba de TAU tras suprimir almagato, este resultado se confirmo en el 97,5%. El porcentaje de falsos negativos sobre el total de casos evaluados fue del 1,8%. Conclusiones La toma de almagato tiene una interferencia minima o nula en el resultado del TAU para el diagnostico de la infeccion por H. pylori; por tanto, se puede utilizar en las semanas previas a la realizacion del TAU.

  • Almagate interference in breath test results for the diagnosis of helicobacter pylori infection
    Revista Espanola De Enfermedades Digestivas, 2014
    Co-Authors: Carles Pons, Sandra Maisterra, Silvia Salord, Angels Pla, David Asensio, Francisco Javier Fernandez, Gerard Traveria
    Abstract:

    Background: Infection by Helicobacter pylori is common and affects both genders at any age. The 13 C-urea breath test is a widely used test for the diagnosis of this infection. However, multiple drugs used for the treatment of Helicobacter pylori infection symptoms have interactions with this breath test that generate false negative results. This observational study was to assess the potential interaction between Almagate and the breath test. Methods: Thirty subjects on Almagate therapy who underwent a breath test were included. If the result was negative, Almagate was withdrawn for a month and the breath test was then repeated. Results: In general, 51.9 % of assessed subjects had a negative result after the first test, and 100 % of these also had a negative result after the second test. Conclusions: It was concluded that the use of Almagate does not interfere in breath test results. These results provide a drug therapy option for the treatment of symptoms associated with Helicobacter pylori infection during the diagnostic process.

A Siles - One of the best experts on this subject based on the ideXlab platform.

R Madero - One of the best experts on this subject based on the ideXlab platform.

  • frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children a prospective study comparing the efficacy of Almagate ranitidine and sucralfate
    Critical Care Medicine, 1992
    Co-Authors: Jesus Lopezherce, P Dorao, P Elola, M A Delgado, F Ruza, R Madero
    Abstract:

    OBJECTIVE To determine the occurrence of upper gastrointestinal hemorrhage in critically ill children, and the efficacy of prophylaxis with Almagate (antacid), ranitidine, and sucralfate. DESIGN Prospective, randomized, controlled trial. SETTING Pediatric ICU of a tertiary care pediatric hospital. PATIENTS During a 2-yr study period, 165 patients with one or more upper gastrointestinal hemorrhage risk factors were randomized into one of four groups. Twenty-five patients were excluded because of protocol violations. A total of 140 patients completed the study, with 35 patients in each group. INTERVENTIONS Patients received no treatment in the control group. The antacid group received Almagate 0.25 to 0.5 mL/kg every 2 hrs by nasogastric tube. The ranitidine group received 1.5 mg/kg every 6 hrs iv. The sucralfate group received 0.5 to 1 g every 6 hrs by nasogastric tube. METHODS Gastric pH and macroscopic bleeding were determined every 2 hrs in all patients until the end of the study. Macroscopic bleeding was classified as nonhemorrhage, slight, or important. Microscopic gastric bleeding was researched with guaiac testing in 72 patients (680 samples). The severity of illness was evaluated by using the Therapeutic Intervention Scoring System, Physiologic Stability Index, and the Multiorgan System Failure scores. The risk of upper gastrointestinal hemorrhage was evaluated by the Zinner and Tryba indices, and was modified for children. MEASUREMENTS AND MAIN RESULTS The occurrence rate of important upper gastrointestinal hemorrhage was higher (by 20%) in the control group than in the rest of the groups (5.7%), p less than .01. There were no differences between the other groups (Almagate 5.7%, ranitidine 8.5%, and sucralfate 2.8%). There was a statistically significant correlation between the occurrence rate of important upper gastrointestinal hemorrhage, the scores of severity of illness indices (Therapeutic Intervention Scoring System, Physiologic Stability Index, and the Multiorgan System Failure scoring system), the risk of upper gastrointestinal hemorrhage indices (Zinner and Tryba), and mortality rate. The Zinner index better classified the patients in relation to the onset of important upper gastrointestinal hemorrhage (sensitivity 76.9%, specificity 85.8%). CONCLUSIONS Upper gastrointestinal hemorrhage is an important complication in critically ill children. Prophylaxis with Almagate, ranitidine, or sucralfate reduces the occurrence rate of clinically important gastrointestinal hemorrhage.